 Cardiff Oncology Inc NASDAQ: CRDF has announced new data from Phase 1b2 evaluating onvansertib in combination with standard-of-care SOC FOLFIRIbevacizumab for second-line KRAS-mutated metastatic colorectal cancer mCRC. Related Content: Cardiff Oncologys Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients. 